Revenue segments as reported by the company.

Online Revenue

Wholesale Revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing

Operations and support

Technology and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Hims & Hers Health achieves record revenue and profitability growth

Hims & Hers Health shows strong financial performance with revenue growth and profitability milestones.
The company's focus on customer-centric strategies, brand building, and innovation drives growth.
Challenges include competition in new categories and maintaining margins on personalized products.
Opportunities lie in expanding product offerings, improving customer experience, and leveraging efficiencies.

Hims & Hers Health excels in Q1 earnings, eyes strategic growth

Hims & Hers Health delivered robust financial performance in Q1 2023, driven by revenue growth, improved margins, and disciplined expense management.
The company's strengths lie in its focus on trusted brands, innovation in product offerings, and commitment to clinical excellence, fostering consumer trust and loyalty.
While challenges like insurance reimbursement and new category entries exist, they present opportunities for strategic growth and market differentiation in the healthcare sector.

Hims & Hers Health (HIMS) reports robust Q2 earnings, eyes personalized healthcare growth

Hims & Hers Health delivered strong financial performance in Q2, driven by revenue growth, expanded gross margins, and operational efficiency. While facing short-term challenges from pricing investments, the company remains focused on long-term growth through personalized treatments and new category launches. Opportunities lie in leveraging consumer trends towards personalized healthcare and expanding product offerings.

Hims & Hers Health reports robust Q3 performance and growth opportunities

Hims & Hers Health (HIMS) showcased strong performance, innovation, and resilience in Q3, driving revenue growth, subscriber base expansion, and improved profitability.
While challenges like achieving positive net income and balancing growth with new category launches exist, the company's strategic initiatives and focus on customer value creation position it for future success.
Opportunities in the weight management category, personalized products, and efficiency gains present avenues for HIMS to capitalize on market trends and enhance its competitive edge.
With a solid financial position, a clear marketing strategy, and a commitment to customer engagement, HIMS is poised for continued growth and value creation in the healthcare sector.

Hims & Hers Health reports stellar Q4 performance and growth outlook

Hims & Hers Health delivered a strong performance in Q4 2023, with robust revenue growth, positive net income, and expanded gross margins.
The company's focus on personalized solutions, subscriber growth, and financial strength positions it well for future growth and market expansion.
While facing challenges in managing costs and margin expansion, HIMS has opportunities to drive revenue growth, enhance user experience, and offer a diverse product range.
By balancing its strengths, addressing challenges, and seizing opportunities, Hims & Hers Health is poised for continued success in the healthcare market.

Hims & Hers Health reports stellar Q1 results and eyes expansion

Hims & Hers Health's Q1 2024 performance reflects strong financial growth, driven by record subscriber numbers and revenue increase, underpinned by a strategic focus on personalized care and enhancing customer experience.
The company's strengths lie in their ability to drive consumer adoption through user-friendly solutions, capitalize on the rapid growth of the Hers segment, and maintain consumer confidence through strategic pricing initiatives.
While facing challenges in scaling operations and managing increased capital expenditures, HIMS has ample opportunities to expand their offerings, invest in new product categories, and drive further revenue growth through strategic pricing adjustments.

Hims & Hers Health posts stellar Q2 results, eyes revenue diversification

Hims & Hers Health (HIMS) reported impressive Q2 performance, with strong revenue growth and subscriber additions.
The company's strategic initiatives in weight management and sterile compounded medications position it for future success.
While facing challenges in data availability and market dynamics, Hims & Hers has opportunities for revenue diversification and enhanced customer engagement.

Hims & Hers Health (HIMS) reports stellar Q3 results and eyes growth through personalized healthcare

Hims & Hers Health's Q3 performance reflects strong revenue growth, subscriber expansion, and improved profitability, positioning the company for continued success.
While facing challenges in retention and operational efficiency, the company's strategic initiatives and market positioning offer opportunities for sustained growth and innovation.
With a focus on personalized healthcare solutions and social responsibility, Hims & Hers Health is well-positioned to capitalize on market opportunities and drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hims was founded in November 2017 after Andrew Dudum was called out by his sister for having dry skin and breakouts. After she ordered him expensive products to address his issues, Dudum realized that men don't have the same options as women when it comes to purchasing wellness products. 

Now with radiant skin, Andrew Dudum and Jack Abraham co-found HIMS as an Atomic (VC fund) portfolio company. The company initially sells hair loss treatments, biotin vitamins, shampoo, and erectile dysfunction treatments. 

The company raises $7 million in Series A from M/C Partners, SV Angel and Thrive Captial, putting its pre-money valuation at $13 million.

Hims raises $40 million in Series B led by IVP and Redpoint Ventures, putting its pre-money valuation at $160 million. 

Hims launches a women's brand, Hers. 

Hers offers telemedicine services, birth control, and non-prescription hair and skin-care products. 

The company partners with A-list couple Jennifer Lopez and Alex Rodriguez, who work with the company on the launch of new products. 

Hims raises $297 million in Series C funding led by DCM Ventures, NewView Capital, McKesson Ventures, putting its valuation at $1 billion.

Hims and Hers expands into virtual mental health services led by licensed professionals, with support groups available free of charge during the COVID-19 pandemic. 

The company now provides access to medical care and treatment for more than a dozen conditions with more than 50 products, and has facilitated 1 million medical visits through its telehealth platforms in 2019. 

Hims goes public through a merger with a blank-check company Oaktree Acquisition Corp at $1.6 billion valuation.

forhims.com/aboutus
forhims.com/investors
SEC
CNBC
Business Insider
Bloomberg
Crunchbase
Axios

Hims & Hers has been beset by unrelenting selling pressure since it reached all-time highs last year. This has come against financial results that continue to outperform consensus estimates.

Hims & Hers: The Market Has Lost Its Mind

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the trusted consumer-first platform focused on providing modern personalized health and wellness experiences to consumers, today announced that it will report third quarter 2022 financial results after the market closes on Monday, November 7, 2022.

Hims & Hers to Announce Third Quarter 2022 Earnings on November 7, 2022

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the trusted consumer-first platform focused on providing modern personalized health and wellness experiences to consumers, has added two high-profile executives to its leadership ranks as the company continues to deliver improving financial performance, including rapid topline growth and increasing scale.

Hims & Hers appoints Chief Communications Officer & VP of Fulfillment Operations

Hims & Hers has now reported back-to-back quarters with over 100K net new subscriptions. The telehealth platform expects to approach a $540 million annual sales run rate in Q4.

Hims & Hers: Just What The Doctor Ordered

Doximity

GoodRx Holdings

These three businesses have lower valuations than Signify.

Amazon Lost Signify: 3 Healthcare Companies That May Be Better Options

American Well Corporation

Teladoc

Amazon will shut down its healthcare service business. Telehealth stocks are rising Thursday.

Teladoc Health Gains on Amazon Care's Loss. These Stocks Are Also Rising.

Direct-to-patient healthcare is the future. H&H's mission is to make healthcare accessible, affordable, and convenient for everyone.

Hims & Hers: Here's A Prescription For Portfolio Dysfunction

Up 109% In 3 Months, This Monster Growth Stock Isn't Done Climbing Yet

Hims & Hers Health, Inc. (NYSE:HIMS ) Q2 2022 Earnings Conference Call August 8, 2022 5:00 PM ET Company Participants Jay Spitzer - Senior Vice President, Investor Relations Andrew Dudum - Chief Executive Officer Yemi Okupe - Chief Financial Officer Conference Call Participants Dan Grosslight - Citigroup Charlotte Kolb - Bank of America Jessica Tassan - Piper Sandler Maxi Ma - Deutsche Bank Jack Wallace - Guggenheim Securities Ivan Feinseth - Tigress Financial Joy Zhang - SVB Securities Operator Ladies and gentlemen, thank you for standing by. My name is Brent, and I will be your operator today.

Hims & Hers Health, Inc. (HIMS) CEO Andrew Dudum on Q2 2022 Results - Earnings Call Transcript

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the trusted consumer-first platform focused on providing modern personalized health and wellness experiences to consumers, today reported financial results for the second quarter ended June 30, 2022. “Our second quarter results were outstanding. Each day, our platform is enabling deep, emotional, and personalized connections, helping to solve consumer health and wellness challenges with authenticity an

Hims & Hers Health, Inc. Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Outlook

What stock soars 30% in this market? Hims & Hers.

This Stock Is Up 30% in 1 Month, With More Upside Ahead

Hims & Hers Health, Inc. (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hims & Hers Health, Inc. (HIMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Hims is a stock which the market has punished beyond what is rational. The company is progressing nicely towards profitability and the share price should begin to creep up. The company's value proposition will lead to a solid moat. The company's effort to vertically integrate will expedite this process.

Hims & Hers Health: Promising Return Profile

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, will release its second quarter 2022 financial results on Monday, August 8, 2022 at 4:15 p.m. E.T., with a conference call to follow at 5:00 p.m. E.T. Conference Call Details The conference call can be accessed by dialing +1 (888) 510-2630 for U.S. participants and +1 (646) 960

Hims & Hers Health, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 8, 2022

Hims & Hers has the growth and the cash to last.

This Former SPAC Looks Recession-Proof

Comera Life Sciences Holdings Inc

Nerdy

Penny stocks to watch right now. The post 3 Top Stocks To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Stocks To Watch Before Next Week

Canaan Inc.

Gevo

Nokia

Offerpad Solutions

Payoneer Global

Transocean

Many penny stocks (stocks trading for less than $5 per share) have little analyst coverage, but these seven have sell-side "buy" ratings. The post 7 Penny Stocks That Actually Have Analyst Buy Ratings appeared first on InvestorPlace.

7 Penny Stocks That Actually Have Analyst Buy Ratings

Hims is a rapidly growing Telehealth company, which is providing significant value to its customers. The business has more positives going for it than negatives. The ever-declining stock price doesn't reflect the solid business behind it. The stock is in a free fall with no bottom in sight; however, that trend should reverse sharply.

Hims & Hers Health: Undervalued Company With Tremendous Upside

SAN FRANCISCO--(BUSINESS WIRE)--Internationally recognized drag superstars Violet Chachki and Gottmik have come together for their first tour to celebrate Pride season.

Hims & Hers Announces 2022 Pride Tour Partnership with Drag Superstars Violet Chachki, Gottmik, and LGBTQ Youth Support Organization, The Trevor Project

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers is revealing today, Hers Wellness Essentials, six new supplements formulated specifically for women.

Hers Doubles Down On Commitment To Women's Wellness With Launch of 6 New Hers Wellness Essentials Supplements

Investors could be overlooking an attractive investment opportunity with Hims & Hers right now.

This Growth Stock Expects Sales to Rise by at Least 51% This Year

In this note, we will discuss Hims & Hers' Q1 2022 report. Hims & Hers is delivering exceptional numbers on almost all KPI metrics. The stock keeps going lower, but the fundamentals are improving with each passing quarter.

Hims & Hers: Improving Fundamentals + Declining Price = A Generational Buy

Hims & Hers Health, Inc. (NYSE:HIMS ) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET Company Participants Jay Spitzer - Senior Vice President and Investor Relations Andrew Dudum - Co-Founder and our Chief Executive Officer Yemi Okupe - Chief Financial Officer Conference Call Participants Daniel Grosslight - Citigroup Michael Cherny - Bank of America Jack Wallace - Guggenheim Jessica Tassan - Piper Sandler Operator Good afternoon. My name is Emma, and I will be your conference operator today.

Hims & Hers Health, Inc. (HIMS) CEO Andrew Dudum on Q1 2022 Results - Earnings Call Transcript

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals and provides access to related prescription fulfillment, today reported financial results for the first quarter ending March 31, 2022. “We kicked off 2022 with breakout performance, executing with strength against all facets of our long-term strategy and financial goals. Investments in platform infrastruc

Hims & Hers Health, Inc. Reports First Quarter 2022 Financial Results and Raises Full Year 2022 Revenue Outlook

Big things could be happening at this telehealth company.

News for Hims & Hers Health Stock (HIMS)